Skip to main content

Table 4 Multiple regression analysis results using ANS activity, age, sex, smoking status, BMI, PANSS, CYP1A2 rs762551 genotype, and UGT1A4 rs2011425 genotype as independent variables in participants treated with olanzapine monotherapy

From: The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine

Independent variableANS activity
Age (years)−0.027< 0.001 d−0.0020.804−0.0190.009 d
BMI (kg/m2)−0.0200.367−0.0010.973−0.0110.612
PANSS total score0.0080.228−0.0130.1130.0030.649
CPZeqa (mg/day)−0.0010.006 d0.0010.699−0.0010.031 d
BPDeqb (mg/day)0.0450.512−0.0120.8850.0390.556
DZPeqc (mg/day)0.0040.6670.0000.9720.0000.997
Type of CYP1A2 rs762551 genotype (reference category: A allele carrier)0.4720.0620.5090.0950.4560.062
Type of UGT1A4 rs2011425 genotype (reference category: G allele carrier)−0.7050.008 d0.3240.302−.3690.143
  1. ANS Autonomic nervous system, BMI Body mass index, ln natural log-transformed, HF High frequency, LF Low frequency, PANSS Positive and Negative Syndrome Scale, TP Total power
  2. aThe daily dosages of antipsychotic drugs were converted to approximate chlorpromazine equivalents
  3. bThe daily dosages of anticholinergic antiparkinsonian drugs were converted to approximate biperiden equivalents
  4. cThe daily dosages of benzodiazepine were converted to approximate diazepam equivalents
  5. dSignificant difference (P < 0.05; multiple regression analysis)